Eprosartan
From Wikipedia, the free encyclopedia
 |
|
|
Eprosartan
|
|
| Systematic (IUPAC) name | |
| 4-[[2-butyl-5-(2-carboxy-3-thiophen-2-yl-prop-1-enyl)-
imidazol-1-yl]methyl]benzoic acid |
|
| Identifiers | |
| CAS number | |
| ATC code | C09 ? |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C23H24N2O4S |
| Mol. mass | Eprosartan mesylate: 520.625 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 15% (Eprosartan mesylate) |
| Metabolism | not metabolized |
| Half life | 5 to 9 hours |
| Excretion | Renal 10%, biliary 90% |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
? |
| Routes | Oral |
Eprosartan is an angiotensin II receptor antagonist used for the treatment of high blood pressure. It is marketed as Teveten by Abbott Laboratories in the United States and by Solvay Pharmaceuticals elsewhere. It is sometimes paired with hydrochlorothiazide, marketed in the US as Teveten HCT and elsewhere as Teveten Plus.
The drug acts on the renin-angiotensin system in two ways to decrease total peripheral resistance. First, it blocks the binding of angiotensin II to AT1 receptors in vascular smooth muscle, causing vascular dilatation. Second, it inhibits sympathetic norepinephrine production, further reducing blood pressure.
As with other angiotensin II receptor antagonists, eprosartan is generally better tolerated than enalapril (an ACE inhibitor), especially among the elderly.[1]
[edit] External links
[edit] References
- ^ Ruilope L, Jäger B, Prichard B (2001). "Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial". Blood Press. 10 (4): 223-9. doi:. PMID 11800061.
|
|||||||||||
